Taiwanese biotech OBI Pharma plans to plough on with a Phase III study of its investigational cancer vaccine OBI-822/821, despite it failing to meet the primary endpoint in a Phase II/III study. The firm's share price fell by from TWD681 to close at TWD613 on Feb. 22 and slipped a further 9.95% to close at TWD522 on Feb. 23 on Taiwan's GreTai Securities Market following the news.
Top-line data show that the first-in-class product, described as an active immunotherapy, did not meet the primary efficacy endpoint of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?